Skip to content
Research Article Open access CC BY 4.0

Assessment of Lipid Profile and Serum Creatinine Kinase in Subjects with Hyperlipidemia on Moderate Intensity Statin Therapy Attending a Postgraduate Teaching Hospital in South India

T. K. Mohammed Muneersha, R. T. Saravanakumar, K. G. Revikumar

Journal of Pharmaceutical Research International · pp. 1–10 · Published 10 Feb 2021

10.9734/jpri/2021/v33i131132

Abstract

Atherosclerosis of large and medium sized arteries are believed to be the major reason behind the development of Coronary Artery Diseases and Hyperlipidemia has been found to be one of the most important contributing factors. Appropriate lifestyle changes along with proper drug therapy lead to a considerable reduction in mortality rate due to coronary artery disease. Reduction of LDL Cholesterol is the primary goal of cholesterol-lowering therapy, but most of the patients are usually unable to achieve the treatment goals with lifestyle modifications alone; and in such situations, drug therapy is essential to prevent the disease progression and further future complications. The aim of the study was to demonstrate impact of three moderate intensity statins on lipid profile and biomarker representing muscle toxicity. It was a prospective observational study conducted in a tertiary care teaching hospital in south India. Patients of both gender falling the age group between 30 and 70 years with newly diagnosed Hyperlipidemia attending the Department of Medicine OPD, were enrolled in the study. Total 229 participants were enrolled in study and all the drug treatment were found to be effective in achieving the treatment goal; at the same time Rosuvastatin 10 mg treatment group exhibited better efficacy along with minimal muscle toxicity.

Atherosclerosis cardiovascular diseases lipid profile serum creatinine kinase statin therapy.

Cited by 1

Effects of Catha edulis Extract on Atorvastatin-Induced Myotoxicity in Rats: Biochemical and Histopathological Evidence

A. M. M. Abbas, S. A. A. Alrezami, B. A. Al-Amrani · Journal of Experimental Pharmacology · 2025

Article metrics

Real usage data collected on this platform.

18

Page views

0

PDF downloads

1

Outbound clicks

1

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.